WO2000014217A3 - G-motif oligonucleotides and uses thereof - Google Patents

G-motif oligonucleotides and uses thereof Download PDF

Info

Publication number
WO2000014217A3
WO2000014217A3 PCT/EP1999/006502 EP9906502W WO0014217A3 WO 2000014217 A3 WO2000014217 A3 WO 2000014217A3 EP 9906502 W EP9906502 W EP 9906502W WO 0014217 A3 WO0014217 A3 WO 0014217A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide
present
composition
oligonucleotide
sequence
Prior art date
Application number
PCT/EP1999/006502
Other languages
French (fr)
Other versions
WO2000014217A2 (en
Inventor
Hermann Wagner
Grayson B Lipford
Klaus Heeg
Original Assignee
Cpg Immunopharmaceuticals Gmbh
Hermann Wagner
Grayson B Lipford
Klaus Heeg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpg Immunopharmaceuticals Gmbh, Hermann Wagner, Grayson B Lipford, Klaus Heeg filed Critical Cpg Immunopharmaceuticals Gmbh
Priority to EP99946118A priority Critical patent/EP1108017A2/en
Priority to CA002341338A priority patent/CA2341338A1/en
Priority to AU58603/99A priority patent/AU777225B2/en
Publication of WO2000014217A2 publication Critical patent/WO2000014217A2/en
Publication of WO2000014217A3 publication Critical patent/WO2000014217A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition comprising an oligonucleotide comprising (a) the sequence N1-N2-G-N3-G, wherein N1 represents any nucleotide if N2 and N3 are G; N2 represents any nucleotide if N1 and N3 are G; and N3 represents any nucleotide if N1 and N2 are G, or (b) the sequence of (a), wherein at least one nucleotide is replaced by a corresponding nucleotide analog or derivative. The present invention further relates to the use of the composition, and/or the oligonucleotide of the present invention for the production of a pharmaceutical composition for preventing or treating septic shock, inflammation, autoimmune diseases, TH1-mediated diseases, bacterial infections, parasitic infections, viral infections, spontaneous abortions, and/or tumors.
PCT/EP1999/006502 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof WO2000014217A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99946118A EP1108017A2 (en) 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof
CA002341338A CA2341338A1 (en) 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof
AU58603/99A AU777225B2 (en) 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98116652 1998-09-03
EP98116652.3 1998-09-03

Publications (2)

Publication Number Publication Date
WO2000014217A2 WO2000014217A2 (en) 2000-03-16
WO2000014217A3 true WO2000014217A3 (en) 2000-07-13

Family

ID=8232574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006502 WO2000014217A2 (en) 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof

Country Status (4)

Country Link
EP (1) EP1108017A2 (en)
AU (1) AU777225B2 (en)
CA (1) CA2341338A1 (en)
WO (1) WO2000014217A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723022B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7776344B2 (en) 1999-09-27 2010-08-17 University Of Iowa Research Foundation Methods related to immunostimulatory nucleic acid-induced interferon
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
AU2003219383B2 (en) 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
ATE544466T1 (en) 2002-10-29 2012-02-15 Coley Pharm Group Inc USE OF CPG OLIGONUCLEOTIDES TO TREAT HEPATITIS C VIRUS INFECTION
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
KR101107818B1 (en) 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 C-class oligonucleotide analogs with enhanced immunostimulatory potency
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
PT1957647E (en) 2005-11-25 2015-06-01 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
ES2427994T3 (en) 2006-06-12 2013-11-05 Cytos Biotechnology Ag Processes for packaging oligonucleotides into viral bacterial phage particles
US7879812B2 (en) 2007-08-06 2011-02-01 University Of Iowa Research Foundation Immunomodulatory oligonucleotides and methods of use therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024380A1 (en) * 1995-02-09 1996-08-15 Icn Pharmaceuticals, Inc. Methods and compositions for regulation of cd28 expression
WO1998029430A1 (en) * 1996-12-27 1998-07-09 Icn, Pharmaceuticals, Inc. G-rich oligo aptamers and methods of modulating an immune response
WO1998032462A1 (en) * 1997-01-23 1998-07-30 Hermann Wagner Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024380A1 (en) * 1995-02-09 1996-08-15 Icn Pharmaceuticals, Inc. Methods and compositions for regulation of cd28 expression
WO1998029430A1 (en) * 1996-12-27 1998-07-09 Icn, Pharmaceuticals, Inc. G-rich oligo aptamers and methods of modulating an immune response
WO1998032462A1 (en) * 1997-01-23 1998-07-30 Hermann Wagner Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALLAS, Z. ET AL.: "INDUCTION OF NK ACTIVITY IN MURINE AND HUMAN CELLS BY CPG MOTIFS IN OLIGODEOXYNUCLEOTIDES AND BACTERIAL DNA", JOURNAL OF IMMUNOLOGY, vol. 157, no. 5, September 1996 (1996-09-01), pages 1840-1845, XP002053416, ISSN: 0022-1767 *
KIMURA Y ET AL: "BINDING OF OLIGOGUANYLATE TO SCAVENGER RECEPTORS IS REQUIRED FOR OLIGONUCLEOTIDES TO AUGMENT NK CELL ACTIVITY AND INDUCE IFN", JOURNAL OF BIOCHEMISTRY, vol. 116, no. 5, November 1994 (1994-11-01), pages 991 - 994, XP000616565, ISSN: 0021-924X *
KRIEG A M ET AL: "THE ROLE OF CpG DINUCLEOTIDES IN DNA VACCINES", TRENDS IN MICROBIOLOGY, vol. 6, no. 1, January 1998 (1998-01-01), pages 23 - 26, XP000857633, ISSN: 0966-842X *
KRIEG, A.: "Leukocyte stimulation by oligodeoxynucleotides", STEIN, C.A. & KRIEG, A.M. 'APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY'. WILEY-LISS, NEW YORK, US;1998; CHAPTER 24, pages 431 - 448, XP002131392 *
LANG R. ET AL.: "Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells.", EUR J IMMUNOL 1999 NOV;29(11):3496-506, XP000876859 *
PISETSKY DS. ET AL.: "The influence of base sequence on the immunostimulatory properties of DNA.", IMMUNOL RES 1999;19(1):35-46, XP000884065 *
SPARWASSER, T. ET AL.: "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.", EUR J IMMUNOL 1998 JUN;28(6):2045-54, XP002131393 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723022B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7776344B2 (en) 1999-09-27 2010-08-17 University Of Iowa Research Foundation Methods related to immunostimulatory nucleic acid-induced interferon
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US8658607B2 (en) 2002-04-04 2014-02-25 Zoetis Belgium Immunostimulatory G, U-containing oligoribonucleotides
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date
EP1108017A2 (en) 2001-06-20
CA2341338A1 (en) 2000-03-16
AU5860399A (en) 2000-03-27
AU777225B2 (en) 2004-10-07
WO2000014217A2 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
WO2000014217A3 (en) G-motif oligonucleotides and uses thereof
FI946201A0 (en) Self-stabilized oligonucleotides as therapeutic agents
AU6589094A (en) 7-deazapurine modified oligonucleotides
WO2000061151A3 (en) Oligodeoxynucleotide and its use to induce an immune response
EP1293503A4 (en) Triazole derivatives
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
ATE465168T1 (en) XYLO-LNA ANALOGUE
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
DE50214266D1 (en) METHOD FOR INHIBITING THE EXPRESSION OF A TARGET AND MEDICAMENT FOR THE THERAPY OF TUMORARY DISEASE
DE69934227D1 (en) ON BETA ARABINOSIS, AND ITS ANALOGS, BASED ANTISENSE OLIGONUCLEOTIDES
WO2002085925A3 (en) Melanocortin receptor ligands
ES2194779T3 (en) 1-AMINOTRIAZOLO (4,3-A) QUINAZOLIN-5-ONAS AND / OR 5-PHOSPHODIESTERASE INHIBITING TIONAS IV.
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
ES2188760T3 (en) SPECIFIC OLIGONUCLEOTIDES FOR THE VIRUS OF HEPATITIS B.
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
EP0775745A3 (en) Cathepsin G-inhibiting aptamers
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2005046587A3 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
HUP9702251A2 (en) Multifunctional ligand system for cell-specific transfer of nucleic acid
AU1070501A (en) Quantitation of rna transcripts using genomic dna as the internal amplification competitor
WO2003101405A3 (en) Aminoglycoside antibiotics and methods of using same
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
WO2005025487A3 (en) Oligonucleotides targeting prion diseases
CA2175368A1 (en) Proliferation antagonistic inhibitor of mesenchymal cells
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2341338

Country of ref document: CA

Ref country code: CA

Ref document number: 2341338

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 58603/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999946118

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999946118

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09786436

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999946118

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 58603/99

Country of ref document: AU